Aura Biosciences (AURA) Operating Leases (2021 - 2026)

Aura Biosciences (AURA) has 6 years of Operating Leases data on file, last reported at $13.7 million in Q1 2026.

• Quarterly Operating Leases fell 10.14% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (down 10.14% YoY) and the FY2025 annual result came in at $14.1 million, down 9.51% from the prior year.
• Operating Leases eased to $13.7 million in Q1 2026, from $14.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.1 million in Q3 2022 to a low of $51000.0 in Q2 2022.
• A 5-year average of $14.3 million and a median of $16.0 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases soared 34031.37% — and 2026, when it retreated 10.14%.
• Tracing AURA's Operating Leases over 5 years: stood at $17.9 million in 2022, then retreated by 5.73% to $16.9 million in 2023, then dropped by 7.41% to $15.6 million in 2024, then slipped by 9.51% to $14.1 million in 2025, then slipped by 2.9% to $13.7 million in 2026.
• The last three Operating Leases figures came in at $13.7 million (Q1 2026), $14.1 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.